1. Search Result
Search Result
Results for "

immunostimulatory and antitumor activities

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

7

Inhibitory Antibodies

2

Natural
Products

Cat. No. Product Name Target Research Area Image
  • HY-P990980

    CND-106; EMB-06

    CD3 Inflammation/Immunology Cancer
    Cizutamig (CND-106) is a bispecific T-cell engager targeting BCMA and CD3. Cizutamig exhibits immunostimulatory and anti-tumor activities. Cizutamig can be used in research related to relapsed or refractory multiple myeloma and systemic lupus erythematosus .
    Cizutamig
  • HY-P991160

    IMM-47

    Inhibitory Antibodies Inflammation/Immunology Cancer
    Suvonstobart is a monoclonal antibody targeting human CD24 (signal transducer CD24). Suvonstobart specifically binds to CD24, activating relevant immune cell signaling pathways and exerting immunostimulatory and antitumor activities .
    Suvonstobart
  • HY-P991125

    YH-002

    TNF Receptor Inflammation/Immunology Cancer
    Cenzestotug is a monoclonal antibody targeting human tumor necrosis factor receptor superfamily member 4 (TNFRSF4). Cenzestotug activates relevant immune cells by binding to TNFRSF4, exerting immunostimulatory and antitumor activities. Cenzestotug is promising for research of cancer immunotherapy .
    Cenzestotug
  • HY-P991397

    Tim3 Cancer
    Sym023 is a human monoclonal antibody (mAb) targeting TIM-3/HAVCR2/CD366. Sym023 enhances immunostimulatory and anti-tumor activities. Sym023 can be used in Non-small cell lung cancer, Solid tumors and Lymphoma research .
    Sym023
  • HY-P991126

    YH003

    TNF Receptor Inflammation/Immunology Cancer
    Ciltistotug is a monoclonal antibody targeting human CD40 (TNFRSF5). Ciltistotug activates immune cells after binding to CD40, exerting immunostimulatory and antitumor activities. Ciltistotug is promising for research of cancer immunotherapy .
    Ciltistotug
  • HY-P990986

    Interleukin Related Inflammation/Immunology Cancer
    Efdelikofusp alfa is a bispecific Fc fusion protein. Efdelikofusp alfa is formed by fusing the N-terminal extracellular domain of human CD80 (B7.1) with the Fc fragment of human immunoglobulin G4 (IgG4), and is linked to an interleukin-2 variant (IL-2v) as the C-terminal part. Efdelikofusp alfa exhibits potential immunostimulatory, immune checkpoint inhibitory, and antitumor activities.
    Efdelikofusp alfa
  • HY-P990992

    GI-102

    Interleukin Related Inflammation/Immunology Cancer
    Efzilonkofusp alfa is a bispecific Fc fusion protein. Efzilonkofusp alfa is formed by fusing the N-terminal extracellular domain of human CD80 (B7.1) with the Fc fragment of human immunoglobulin G4 (IgG4), and is linked to an interleukin-2 variant (IL-2v) as the C-terminal part. Efzilonkofusp alfa exhibits potential immunostimulatory, immune checkpoint inhibitory, and antitumor activities.
    Efzilonkofusp alfa

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: